Down-regulation of bax-interacting factor 1 in human pancreatic ductal adenocarcinoma

Pancreas

Volumn 40, Issue 3, 2011, Pages 433-437

  Coppola, Domenico ^a,b   Helm, James ^a,b   Ghayouri, Msoumeh ^a   Malafa, Mokenge P ^a,b   Wang, Hong Gang ^c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Bif 1; immunohistochemistry; outcomes; pancreatic ductal adenocarcinoma; tissue microarray

Indexed keywords

BAX INTERACTING FACTOR 1; ENDOPHILIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER INVASION; CANCER SIZE; CANCER SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PANCREAS DUCTAL ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL RATE; TISSUE MICROARRAY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PANCREAS; PANCREATIC NEOPLASMS; PROGNOSIS; PROTEIN ARRAY ANALYSIS;

EID: 79954423742     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e318205eb03     Document Type: Article

References (47)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
2. Jemal A, Thomas A, Murray T, et al. Cancer statistics, 2002. CA Cancer J Clin. 2002;52:23-47.
3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70. (Pubitemid 30046295)
5. Miyamoto Y, Hosotani R, Wada M, et al. Immunohistochemical analysis of Bcl-2, Bax, Bcl-X, and Mcl-1 expression in pancreatic cancers. Oncology. 1999;56:73-82. (Pubitemid 29043900)
6. Wilentz RE, Iacobuzio-Donahue CA, Argani P, et al. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res. 2000;60:2002-2006. (Pubitemid 30207663)
7. Barton CM, Hall PA, Hughes CM, et al. Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer. J Pathol. 1991;163:111-116.
8. Korc M, Meltzer P, Trent J. Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer. Proc Natl Acad Sci U S A. 1986;83:5141-5144. (Pubitemid 16051332)
9. Szepeshazi K, Halmos G, Schally AV, et al. Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs. J Cancer Res Clin Oncol. 1999;125:444-452. (Pubitemid 29410408)
10. DiGiuseppe JA, Hruban RH, Goodman SN, et al. Overexpression of p53 protein in adenocarcinoma of the pancreas. Am J Clin Pathol. 1994;101:684-688. (Pubitemid 24169297)
11. Lundin J, Nordling S, von Boguslawsky K, et al. Prognostic value of immunohistochemical expression of p53 in patients with pancreatic cancer. Oncology. 1996;53:104-111. (Pubitemid 26087917)
12. Almoguera C, Shibata D, Forrester K, et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1988;53:549-554.
13. Gotoda T, Matsumura Y, Kondo H, et al. Expression of CD44 variants and its association with survival in pancreatic cancer. Jpn J Cancer Res. 1998;89:1033-1040. (Pubitemid 28544779)
14. Castella EM, Ariza A, Ojanguren I, et al. Differential expression of CD44v6 in adenocarcinoma of the pancreas: an immunohistochemical study. Virchows Arch. 1996;429:191-195. (Pubitemid 26402660)
15. Tumminello FM, Leto G, Pizzolanti G, et al. Cathepsin D, B and L circulating levels as prognostic markers of malignant progression. Anticancer Res. 1996;16:2315-2319. (Pubitemid 26265584)
16. Pelosi G, Pasini F, Bresaola E, et al. High-affinity monomeric 67-kd laminin receptors and prognosis in pancreatic endocrine tumours. J Pathol. 1997;183:62-69. (Pubitemid 27368528)
17. Cantero D, Friess H, Deflorin J, et al. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer. 1997;75:388-395. (Pubitemid 27051054)
18. Cuddeback SM, Yamaguchi H, Komatsu K, et al. Molecular cloning and characterization of Bif-1. A novel Src homology 3 domain-containing protein that associates with Bax. J Biol Chem. 2001;276:20559-20565.
19. Pierrat B, Simonen M, Cueto M, et al. SH3GLB, a new endophilin-related protein family featuring an SH3 domain. Genomics. 2001;71:222-234. (Pubitemid 32165089)
20. Takahashi Y, Karbowski M, Yamaguchi H, et al. Loss of Bif-1 suppresses Bax/Bak conformational change and mitochondrial apoptosis. Mol Cell Biol. 2005;25:9369-9382. (Pubitemid 41507838)
21. Karbowski M, Jeong SY, Youle RJ. Endophilin B1 is required for the maintenance of mitochondrial morphology. J Cell Biol. 2004;166:1027-1039. (Pubitemid 39304766)
22. Takahashi Y, Meyerkord CL, Wang HG. Bif-1/endophilin B1: a candidate for crescent driving force in autophagy. Cell Death Differ. 2009;16:947-955.
23. Thoresen SB, Pedersen NM, Liestol K, et al. A phosphatidylinositol 3-kinase class III sub-complex containing VPS15, VPS34, Beclin 1, UVRAG and BIF-1 regulates cytokinesis and degradative endocytic traffic. Exp Cell Res. 2010;316:3368-3378.
24. Wan J, Cheung AY, Fu WY, et al. Endophilin B1 as a novel regulator of nerve growth factor/ TrkA trafficking and neurite outgrowth. J Neurosci. 2008;28:9002-9012.
25. Takahashi Y, Coppola D, Matsushita N, et al. Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. Nat Cell Biol. 2007;9:1142-1151. (Pubitemid 47500490)
26. Gozuacik D, Kimchi A. Autophagy as a cell death and tumor suppressor mechanism. Oncogene. 2004;23:2891-2906. (Pubitemid 38638851)
27. Shintani T, Klionsky DJ. Autophagy in health and disease: a double-edged sword. Science. 2004;306:990-995. (Pubitemid 39482894)
28. Mathew R, White E. Why sick cells produce tumors: the protective role of autophagy. Autophagy. 2007;3:502-505. (Pubitemid 47293740)
29. Green DR, Evan GI. A matter of life and death. Cancer Cell. 2002;1:19-30. (Pubitemid 41039172)
30. Balakrishnan A, von Neuhoff N, Rudolph C, et al. Quantitative microsatellite analysis to delineate the commonly deleted region 1p22.3 in mantle cell lymphomas. Genes Chromosomes Cancer. 2006;45: 883-892. (Pubitemid 44360176)
31. Walker GJ, Indsto JO, Sood R, et al. Deletion mapping suggests that the 1p22 melanoma susceptibility gene is a tumor suppressor localized to a 9-Mb interval. Genes Chromosomes Cancer. 2004;41:56-64. (Pubitemid 38988738)
32. Lee WC, Balsara B, Liu Z, et al. Loss of heterozygosity analysis defines a critical region in chromosome 1p22 commonly deleted in human malignant mesothelioma. Cancer Res. 1996;56:4297-4301. (Pubitemid 26330424)
33. Roberts T, Chernova O, Cowell JK. Molecular characterization of the 1p22 breakpoint region spanning the constitutional translocation breakpoint in a neuroblastoma patient with a t(1;10)(p22;q21). Cancer Genet Cytogenet. 1998;100:10-20. (Pubitemid 128766336)
34. Kakinuma H, Habuchi T, Ito T, et al. BCL10 is not a major target for frequent loss of 1p in testicular germ cell tumors. Cancer Genet Cytogenet. 2001;126:134-138. (Pubitemid 32453330)
35. Mora J, Cheung NK, Kushner BH, et al. Clinical categories of neuroblastoma are associated with different patterns of loss of heterozygosity on chromosome arm 1p. J Mol Diagn. 2000;2:37-46.
36. Emi M, Matsumoto S, Iida A, et al. Correlation of allelic losses and clinicopathological factors in primary breast cancers. Breast Cancer. 1997;4:243-246.
37. Bello MJ, de Campos JM, Vaquero J, et al. High-resolution analysis of chromosome arm 1p alterations in meningioma. Cancer Genet Cytogenet. 2000;120:30-36. (Pubitemid 30410774)
38. Knosel T, Petersen S, Schwabe H, et al. Incidence of chromosomal imbalances in advanced colorectal carcinomas and their metastases. Virchows Arch. 2002;440:187-194. (Pubitemid 34169857)
39. Bonner AE, Lemon WJ, Devereux TR, et al. Molecular profiling of mouse lung tumors: association with tumor progression, lung development, and human lung adenocarcinomas. Oncogene. 2004;23:1166-1176. (Pubitemid 38269970)
40. Ho J, Kong JW, Choong LY, et al. Novel breast cancer metastasis associated proteins. J Proteome Res. 2009;8:583-594.
41. Lee JW, Jeong EG, Soung YH, et al. Decreased expression of tumour suppressor Bax-interacting factor-1 (Bif-1), a Bax activator, in gastric carcinomas. Pathology. 2006;38:312-315. (Pubitemid 44266628)
42. Coppola D, Oliveri C, Sayegh Z, et al. Bax-interacting factor-1 (Bif-1) expression in prostate cancer. Clin Genitourin Cancer. 2008;6(2):117-121.
43. Coppola D, Khalil F, Eschrich S, et al. Down regulation of Bax-interacting factor-1 (Bif-1) in colon cancer. Cancer. 2008;6:117-121.
44. Kim SY, Oh YL, Kim KM, et al. Decreased expression of Bax-interacting factor-1 (Bif-1) in invasive urinary bladder and gallbladder cancers. Pathology. 2008;40:553-557.
45. Ho J, Kong JW, Choong LY, et al. Novel breast cancer metastasis- associated proteins. J Proteome Res. 2009;8:583-594.
46. Kim MS, Yoo NJ, Lee SH. Somatic mutation of pro-cell death Bif-1 gene is rare in common human cancers. APMIS. 2008;116:939-940.
47. Helm J, Centeno BA, Coppola D, et al. Histologic characteristics enhance predictive value of American Joint Committee on Cancer staging in resectable pancreas cancer. Cancer. 2009;115:4080-4089.